April 22 Product: ImmunityBios Anktiva Indication: Non-muscle invasive bladder cancer A large number of bladder cancer patients will have a new treatment option as the FDA on Monday greenlit ImmunityBios Anktiva, a first-in-class IL-15 superagonist for non-muscle invasive bladder cancerwhich accounts for approximately 80% of new cases, according to the company
5 WARNINGS AND PRECAUTIONS Directions And Dosage 2 DOSAGE AND ADMINISTRATION 3 DOSAGE FORMS AND STRENGTHS Injection: clear, colorless solution available in 5 pre-filled, disposable, single-dose pens: 0.25 mg/0.5 mL 0.5 mg/0.5 mL 1 mg/0.5 mL 1.7 mg/0.75 mL 2.4 mg/0.75 mL 10 OVERDOSAGE Overdoses have been reported with other GLP-1 receptor agonists
While human data remains limited, this area is attracting significant research attention particularly relevant in clinical settings where patients use multiple pharmaceuticals that carry hepatotoxic risk
"How Ozempic could affect the health of the global economy in more ways than one"
Low potassium, also known as hypokalemia, can cause muscle weakness, cramps, and irregular heartbeats